The present study results support the utility of the PLASMIC score as a rapid, feasible, and reliable clinical assessment tool to predict severe ADAMTS13 deficiency in adult patients with TMA. This evidence concerns the gene ADAMTS13 and hyperinsulinemic hypoglycemia, familial, 4.